Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Gavel with drugs it is a safe bet that the Trump administration will attempt to redeploy this rule, or that Congress may pass legislation giving HHS the proper authority to regulate price transparency. (Photo: Shutterstock)

Hours before it was scheduled to take effect on July 9th, a federal judge in Washington, D.C. blocked a controversial final rule which would have regulated the marketing of prescription drugs. U.S. District Judge Amit Mehta ruled, to the dismay of many cost-containment advocates, that the Department of Health and Human Services (HHS) lacked the regulatory authority to force drug manufacturers to include the cost of drugs in television commercials. She noted, “[t]hat policy very well could be an effective tool in halting the rising cost of prescription drugs. But no matter how vexing the problem of spiraling drug costs may be, HHS cannot do more than what Congress has authorized.”

BenefitsPRO Broker Expo 2020Event

The premier educational and networking event for employee benefits brokers and agents.

Get More Information


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.